×
Profound Medical EBIT 2020-2024 | PROF
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Profound Medical ebit from 2020 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Profound Medical EBIT 2020-2024 | PROF
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Profound Medical ebit from 2020 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.7B
Takeda Pharmaceutical (TAK)
$42.4B
Sandoz Group AG (SDZNY)
$19.3B
Merck (MKKGY)
$18.8B
Astellas Pharma (ALPMY)
$18.3B
United Therapeutics (UTHR)
$16.4B
Summit Therapeutics (SMMT)
$13.6B
Neurocrine Biosciences (NBIX)
$12.7B
Shionogi (SGIOY)
$11.8B
Catalent (CTLT)
$10.8B
Jazz Pharmaceuticals (JAZZ)
$7.6B
Madrigal Pharmaceuticals (MDGL)
$7.2B
Orion OYJ (ORINY)
$6.7B
Corcept Therapeutics (CORT)
$5.9B
Ionis Pharmaceuticals (IONS)
$5.4B
Crinetics Pharmaceuticals (CRNX)
$5.3B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Soleno Therapeutics (SLNO)
$2.4B
Arrowhead Pharmaceuticals (ARWR)
$2.3B
Centessa Pharmaceuticals (CNTA)
$2.1B
Evotec AG (EVO)
$1.9B
NewAmsterdam Pharma (NAMS)
$1.9B
Xencor (XNCR)
$1.7B
Recursion Pharmaceuticals (RXRX)
$1.6B
Harrow (HROW)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Cassava Sciences (SAVA)
$1.5B